Pacemaker and/or Defibrillator Implantation: Continued Warfarin Outperforms Bridging with Heparin

Authors

  • Dimitrios D. Manolatos Department of Cardiology, Evagelismos Hospital, Athens, Greece

DOI:

https://doi.org/10.2015/hc.v9i1%20Sup.645

Keywords:

pacemaker, defibrillator, oral anticoagulation, warfarin, heparin

Abstract

Among patients undergoing pacemaker or implantable cardioverter-defibrillator (ICD) implantation, approximately 14-45% are on anticoagulation therapy. Recently updated guidelines from the American College of Chest Physicians have recommended use of bridging anticoagulation with therapeutic dose of subcutaneous low-molecularweight heparin or intravenous heparin in patients with mechanical heart valves, atrial fibrillation, or venous thromboembolism who are at moderate or high risk for thromboembolic events (estimated annual stroke risk >5%).

Downloads

Published

2014-05-20

Issue

Vol. 9 No. 1 Sup (2014): ATHENS CARDIOLOGY UPDATE 2014

Section

ATHENS CARDIOLOGY UPDATE 2014

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).